You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

Funded Evidence-Informed Regimens

Drug and regimen monographs and information sheets for patients provide information on dosing and administering cancer treatment protocols. They are for general reference and are not meant to replace prescribing information or physician recommendations.

If you have questions about ST-QBP funding on our website, please visit our Frequently Asked Questions page.

Find enhanced Regimen Patient Information Sheets, created in collaboration with patient and family advisors.

Regimens

12 Items
Cancer Type: Genitourinary, Prostate     
Intent: Neoadjuvant, Adjuvant, Palliative
Funding:
ODB - General Benefit
  • buserelin
ODB - General Benefit
  • bicalutamide
Oct 2016
Cancer Type: Genitourinary, Prostate     
Intent: Neoadjuvant, Adjuvant, Palliative
Funding:
ODB - General Benefit
    triptorelin
ODB - General Benefit
    bicalutamide
Jan 2018
Cancer Type: Genitourinary, Prostate     
Intent: Neoadjuvant, Adjuvant, Palliative
Funding:
ODB - General Benefit
  • buserelin
Oct 2016
Cancer Type: Skin, Melanoma     
Intent: Palliative
Funding:
Exceptional Access Program
    daBRAfenib - In combination with trametinib for the treatment of BRAF V600 mutation-positive, unresectable or metastatic melanoma, according to specific clinical criteria
Exceptional Access Program
    trametinib - In combination with dabrafenib for the treatment of BRAF V600 mutation-positive, unresectable or metastatic melanoma, according to specific clinical criteria
May 2019
Cancer Type: Lung, Non-Small Cell     
Intent: Palliative
Drugs Used:
daBRAFenib (Unfunded),
trametinib (Unfunded)
May 2019
Cancer Type: Skin, Melanoma     
Intent: Adjuvant, Curative
Drugs Used:
daBRAFenib (Unfunded),
trametinib (Unfunded)
May 2019
Cancer Type: Hematologic, Leukemia - Acute Myeloid (AML)     
Intent: Palliative
Drugs Used:
enasidenib (Unfunded)
May 2019
Cancer Type: Hematologic, Leukemia - Chronic Myeloid (CML)     
Intent: Palliative
Funding:
Exceptional Access Program
    ponatinib - For the treatment of Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia, according to specific clinical criteria
Jun 2019
Cancer Type: Hematologic, Leukemia - Acute Lymphoblastic (ALL)     
Intent: Curative, Palliative
Funding:
Exceptional Access Program
    ponatinib - For the treatment of Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL), according to specific clinical criteria
Jun 2019
Cancer Type: Skin, Melanoma     
Intent: Palliative
Funding:
Exceptional Access Program
    trametinib - As monotherapy for the first-line and second-line treatment of patients with BRAF V600 mutation-positive unresectable or metastatic melanoma, according to specific criteria
Jun 2019
Cancer Type: Genitourinary, Prostate     
Intent: Neoadjuvant, Adjuvant, Palliative
Funding:
ODB - General Benefit
  • triptorelin
Jun 2017
Cancer Type: Breast     
Intent: Adjuvant, Curative, Palliative
Funding:
ODB - General Benefit
    triptorelin
May 2019